Towards optimal design of second-generation immunomodulatory oligonucleotides

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 2, 2002, Pages 122-129

  Kandimalla, Ekambar R ^a   Yu, Dong ^a   Agrawal, Sudhir ^a  

^a HYBRIDON INC   (United States)

Author keywords

CpG DNA; CpR DNA; Cytokines; Immunostimulatory; TLR9; YpG DNA

Indexed keywords

ALPHA INTERFERON; ANTISENSE OLIGODEOXYNUCLEOTIDE; BACTERIAL DNA; BETA INTERFERON; CD40 ANTIGEN; CD86 ANTIGEN; COMPLEMENTARY DNA; CYTOSINE DERIVATIVE; DINUCLEOTIDE; DNA VACCINE; DOUBLE STRANDED DNA; GAMMA INTERFERON; GUANINE DERIVATIVE; GUANINE NUCLEOTIDE; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PALINDROMIC DNA; PHOSPHOROTHIOIC ACID DERIVATIVE; PURINE DERIVATIVE; RITUXIMAB; SINGLE STRANDED DNA; TOLL LIKE RECEPTOR; CELL SURFACE RECEPTOR; DNA BINDING PROTEIN; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; TOLL LIKE RECEPTOR 9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL CELL CARCINOMA; CELLULAR IMMUNITY; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CPG ISLAND; DNA SEQUENCE; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMORAL IMMUNITY; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSTIMULATION; LYMPHOMA; MELANOMA; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; SEQUENCE ANALYSIS; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; CONFORMATION; GENETICS; METABOLISM; REVIEW; SYNTHESIS;

ADJUVANTS, IMMUNOLOGIC; CPG ISLANDS; DNA-BINDING PROTEINS; DRUG DESIGN; NUCLEIC ACID CONFORMATION; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 9;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 0035997957     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity
2. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
3. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth
4. Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity
5. CpG motifs in bacterial DNA trigger direct B-cell activation
6. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
7. CpG-rich islands and the function of DNA methylation
8. Toll-like receptors
9. A Toll-like receptor recognizes bacterial DNA
10. Role of Toll-Like Receptor 9 in CpG DNA-induced activation of human cells
11. Bacterial CpG DNA activates immune cells to signal infectious danger
12. DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA
13. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition
14. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12
15. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
16. Introduction to immunostimulatory DNA sequences
17. Immunostimulatory CpG oligodeoxynucleotides stimulate expression of IL-1β and interferon-like cytokines in rainbow trout macrophages via a chloroquine-sensitive mechanism
18. CpG oligodeoxynucleotides and plasmid DNA stimulate Atlantic salmon (Salmo salar L.) leucocytes to produce supernatants with antiviral activity
19. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif
20. CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation
21. Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides
22. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved
23. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells
24. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens
25. Identification of CpG oligonucleotide sequences with high induction of IFNα/β in plasmacytoid dendritic cells
26. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs
27. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs
28. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFNγ production in vitro
29. Designing immune responses with genetic immunization and immunostimulatory DNA sequences
30. DNA vaccines: Immunology, application, and optimization
31. The influence of base sequence on the immunostimulatory properties of DNA
32. Recognition of double-stranded RNA and activation of NFκB by Toll-like receptor 3
33. Polynucleotide binding to macrophage scavenger receptors depends on the formation of base-quartet-stabilized four-stranded helices
34. Effect of G-rich sequences on the synthesis, purification, binding, cell uptake, and hemolytic activity of oligonucleotides
35. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines
36. Antisense therapeutics: Is it as simple as complementary base recognition?
37. Therapeutic potential of synthetic CpG DNA - Current status and future directions
38. Antisense and/or immunostimulatory oligonucleotide therapeutics
39. Medicinal chemistry and therapeutic potential of CpG DNA
40. Effect of different chemically modified oligodeoxynucleotides on immune stimulation
41. Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: Structure-immunostimulatory activity relationships
42. Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases
43. Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity
44. Immunostimulatory activity of CpG containing phosphorothioate oligodexynucleotide is modulated by modification of a single deoxynucleoside
45. Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphoshonate linkages
46. Immunostimulatory properties of phosphorothioate CpG DNA containing both 3′-5′- and 2′-5′-internucleotide linkages
47. Accessible 5′-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity
48. CpG DNA induces cycloxygenase-2 expression and prostaglandin production
49. Host response to infection: The role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages
50. Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus
51. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon-γ
52. Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice
53. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma
54. Distinct CpG oligonucleotide sequences activate human γδ T cells via interferon-αβ
55. CpG oligodeoxynucleotides as vaccine adjuvants in primates
56. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide
57. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides
58. Synergism between cytosineguanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma